Type 2 diabetes and cardiovascular risk factors

Current Medical Research and Opinion

Volumn 27, Issue SUPPL. 3, 2011, Pages 1-5

  Sharma, Morali D ^a   Farmer, John Alan ^a   Garber, Alan ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Hyperlipidemia; Hypertension; Type 2 diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; RENIN INHIBITOR; ROSUVASTATIN; SIMVASTATIN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; DIABETIC DYSLIPIDEMIA; DIABETIC MICROANGIOPATHY; DRUG USE; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; RISK FACTORS;

EID: 81855210981     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.620083     Document Type: Review

References (14)

1. UKPDS 33. Intensive blood-glucose control with sulphonyureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
2. UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. UK Prospective Study (UKPDS) Group. Lancet 1998;352:854-65
3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
4. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59 (Pubitemid 351831356)
5. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72 (Pubitemid 351831357)
6. Duckworth W, Abraira C, Mortiz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
7. Jones PH. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am J Cardiol 2008;102:41L-47L
8. Calhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type II diabetics in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet 2004; 364:685-96 (Pubitemid 39140624)
9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002,360:7-22
10. Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol 2001; 108:523-30
11. Keech A, Simes RJ, Barter P, et al. FIELD Study Investigators: Effect of longterm fenofibrate therapy on cardiovascular events in 9795 people with type II diabetes mellitus (the FIELD Study): randomized controlled trial. Lancet 2005; 366:1849-61
12. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74e
13. UK Prospective Diabetes Study Group. Tight blood pressure control and the risk of macrovascular and microvascular complications in type II diabetes. UKPDS 38. BMJ 1998;317:703-13
14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;351:1755-62 (Pubitemid 28269185)